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Abstract 
Background: A trend of stage‑by‑stage increase in tumorsphere (TS) formation from glioma samples has been 
reported. Despite this trend, not all surgical specimens give rise to TSs, even World Health Organization (WHO) grade 
IV gliomas. Furthermore, it has been reported that differences in overall survival of primary glioblastoma patients 
depends on the propensity of their tumors to form TSs. However, the weights of fresh specimens vary from one surgi‑
cal isolate to the next.
Methods: Accordingly, we evaluated the relationship between the weights of surgical specimens in WHO grade IV 
gliomas with the capacity to isolate TSs. Thirty‑five fresh WHO grade IV glioma specimens were separated into two 
groups, based on whether they were positive or negative for TS isolation, and the relationship between TS isolation 
and weight of surgical specimens was assessed.
Results: We observed no significant difference in the weights of surgical samples in the two groups, and found that 
the optimal weight of specimens for TSs isolation was 500 mg.
Conclusion: Thus, contrary to our expectations, the ability to isolate TSs from WHO grade IV glioma specimens was 
not related to the weight of fresh specimens.
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Background
A subpopulation of glioblastoma (GBM) tumor cells pos-
sesses the ability to undergo neural differentiation and 
induce tumorigenesis [1–3]. When cultured under appro-
priate conditions in vitro, this population of tumor cells 
gives rise to gliomaspheres, referred to more generically 
as tumorspheres (TSs). TSs have been isolated from vari-
ous malignant tumors, including breast [4], prostate [5], 
bone [6], colon [7], kidney [8] and lung [9], as well as 
brain [3, 10–14]. It was previously reported that the rate 
of isolation of TSs increase as the World Health Organi-
zation (WHO) grades of glioma rise [3]. Moreover, it is 
not possible to isolate TSs from GBM specimens in all 
cases, with reported isolation rates estimated at 43.8  % 
[3]. Notably, the ability to isolate TSs is a significant prog-
nostic factor for overall survival in patients with primary 
GBM [15].
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It is known that the weight of fresh specimens varies 
from one surgical procedure to the next. This raises the 
question of whether the weight of a specimen is a deter-
mining factor in the ability to isolate TSs from it. In some 
isolation protocols, it is suggested that a specimen weight 
of 200–500 mg is needed for isolation of TSs [11]. How-
ever, there is no established experimental relationship 
between the weight of fresh specimens and the isolation 
of TSs.
In this study, we assessed the predictive value of fresh 
specimen weight in determining the ability to isolate TSs, 
testing the hypothesis that the greater the weight of the 
specimen, the more effective the isolation of TSs. Thirty-
five fresh specimens of WHO grade IV gliomas were 
divided into two groups, based on the ability to isolate 
TSs from them, and the relationship between specimen 
weight and TSs isolation was studied. We also evaluated 
the optimal cut-off weight of specimens for the isolation 
of TSs.
Methods
Patient population
Patients with WHO grade IV glioma treated at our insti-
tution between October 2014 and August 2015 were 
included in this study (Table  1). All patients were his-
tologically diagnosed according to the 2007 WHO clas-
sification, and were graded by neuropathologists; the 
molecular properties of each surgical specimen have 
been reported [16]. O-6-methylguanine-DNA methyl-
transferase (MGMT) promotor methylation and isoci-
trate dehydrogenase (IDH)-1 mutation status were 
assessed by polymerase chain reaction (PCR) and immu-
nohistochemistry (IHC). In cases where IHC results for 
IDH1 were negative, we tested for IDH1 mutations using 
the hot-spot technique. Epidermal growth factor recep-
tor (EGFR) and loss of heterozygosity (LOH) at chromo-
somes 1p and 19q were evaluated by fluorescence in situ 
hybridization (FISH). P53 was identified by IHC.
From fresh specimen to single cell isolation
Fresh tumor specimens were obtained in the operating 
room from glioma patients undergoing surgery. Each 
specimen was place in a sterile centrifuge tube (SPL Life 
Sciences Co., Ltd, Korea) on ice, and was weighed on the 
same electronic precision balance (Sartorius® TE4101-
L, Sartorius Weighing Technology GmbH, Goettingen, 
Germany) within 1  h. Thereafter, specimens were pro-
cessed using a previously reported mechanical dissocia-
tion method [1, 3, 17]. Briefly, surgical specimens were 
minced and dissociated with a scalpel in Dulbecco’s mod-
ified Eagle medium/nutrient mixture F-12 (DMEM/F-12; 
Mediatech, Manassas, VA, USA) and then passed 
through a series of 100-μm nylon mesh cell strainers (BD 
Falcon, Franklin Lakes, NJ, USA). Cell suspensions were 
washed twice in DMEM/F-12 and cultured in complete 
media (DMEM/F-12) containing 1xB27 supplements 
(Invitrogen, San Diego, CA, USA), 20  ng/ml of basic 
fibroblast growth factor (bFGF; Sigma, St. Louis, MO, 
USA), 20 ng/ml of epidermal growth factor (EGF; Sigma), 
and 50 U/ml penicillin/50 mg/ml streptomycin [1, 3, 17].
Isolation of TSs
Isolated single cells were cultured as gliomaspheres in 
complete TS medium consisting of DMEM/F-12 con-
taining 2 % 1× B27, 20 ng/ml of 0.02 % bFGF, 20 ng/ml 
of 0.02  % EGF, and 1  % antibiotic–antimycotic solution 
(100× ; Gibco, Invitrogen Korea, Seoul, Korea). The cells 
were cultured continuously through three to six passages, 
consistent with their status as progenitor/stem cells. Cell 
morphology was assessed by observing cultures with an 
inverted phase-contrast microscope (I  ×  71 Inverted 
Microscope; Olympus, Tokyo, Japan). The neural differ-
entiation potential of gliomaspheres was subsequently 
tested, followed by an evaluation of their ability to induce 
tumorigenesis in vivo. The relationship between the iso-
lation of TSs and the weight of surgical specimens was 
investigated, and the optimal cut-off weight for isolation 
of TSs was evaluated.
Immunocytochemical staining
For investigation of surface and intracellular antigen 
expression profiles, TSs were transferred to cover slides, 
fixed with 2  % paraformaldehyde for 7  min, and then 
treated with a 3:1 ratio of methanol and acetic acid for 
3  min. The cells were then washed and permeabilized 
by incubating with 0.1 % Triton X-100 for 10 min. After 
blocking with 1 % bovine serum albumin (BSA; Amresco, 
Solon, OH, USA) for 1 h, cells were incubated with pri-
mary antibodies for 2  h at room temperature. The fol-
lowing antibodies were used: rabbit anti-CD133 (1:250, 
ab19898; Abcam [Dawinbio Inc], Hanam, Korea), rabbit 
anti-nestin (1:250, ab5968; Abcam). Primary antibod-
ies against CD133 and nestin were detected with goat 
anti-rabbit IgG conjugated with Alexa Fluor 555 (1:2000; 
Invitrogen), which is spectrally similar to Cy3. The cells 
were mounted with Vectashield H-1200 mounting media 
containing 4′6-diamidino-2-phenylindole (DAPI; Vec-
tor Laboratories, Burlingame, CA, USA) to counter-
stain nuclei. Phosphate-buffered saline (PBS; Dawinbio 
Inc, Hanam, Korea) was used for all washing steps, and 
antibody diluent reagent solution (Invitrogen) was used 
to dilute antibodies. As a negative control, only the sec-
ondary antibody was used. A fluorescence microscope 
(1 × 71; Olympus Korea, Seoul, Korea) and DP Control-
ler software (Olympus Korea) were used for observing 
and photographing the cells.
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Immunohistochemical staining
Sections  (3-mm thick) were deparaffinized in xylene 
and rehydrated through a graded alcohol series to dis-
tilled water. Antigen retrieval was performed by micro-
wave irradiation, after which samples were incubated 
with the following primary antibodies: rabbit polyclonal 
anti-CD133 (1:200, ab19898; Abcam [Dawinbio Inc], 
Hanam, Korea), mouse monoclonal anti-nestin (10C2; 
CELL MARQUE, Rocklin, CA95677, USA), and mouse 
monoclonal anti-CD15 (1:50, M3631; Dako Korea LCC, 
Seoul). Specific binding was detected using biotinylated 
anti-mouse IgG, followed by peroxidase/alkaline phos-
phatase streptavidin, with 3,3′-diaminobenzidine and the 
combination of nitro blue tetrazolium chloride (NBT) 
and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) as 
substrates.
Neuro‑glial differentiation
The multipotency of TSs was tested by examining neu-
ral lineage expression by immunocytochemical staining. 
Briefly, after being seeded onto chamber slides (Lab-Tek 
II; Nalge Nunc International, Rochester, NY, USA), cells 
were grown in neural differentiation media containing 
10 % fetal bovine serum (FBS; Lonza) and 1 × B27 sup-
plement (Invitrogen) for up to 14  days. Cells were then 
fixed with 2 % paraformaldehyde for 7 min at 4  °C, and 
permeabilized by incubating with 0.1 % Triton X-100 for 
10 min. After blocking with 1 % BSA (Amresco) for 1 h, 
cells were immunostained with the following antibodies: 
rabbit anti-GFAP (1:200 dilution; Dako, Carpinteria, CA, 
USA), mouse anti-MBP (myelin basic protein, 1:200 dilu-
tion; Chemicon, Temecula, CA, USA), mouse anti-NeuN 
(1:100 dilution; Chemicon), and mouse anti-TUBB3 
(Tuj1, 1:200 dilution; Chemicon). The primary antibod-
ies were detected with Cy3-conjugated anti-mouse or 
anti-rabbit secondary antibodies (1:200 dilution; Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA), 
as appropriate. Nuclei were counterstained with DAPI 
(Vector Laboratories). Slides were examined and photo-
graphed using a fluorescence microscope.
Statistical analysis
The patients’ demographic characteristics and weight 
of each surgical specimens were compared using the 
Table 1 Demographic and clinical characteristics of patients with WHO grade IV glioma
* By Independent two-sample t test for continuous variables and Chi square test (or Fisher’s exact test) for categorical variables
Characteristics TS culture positive (n = 18) TS culture negative (n = 17) P value*
Age (years) 62.6 ± 10.7 55.5 ± 12.9 0.088
Sex (M:F) 10:8 10:7 0.845
Pathological diagnosis >0.999
 GBM 14 (77.8 %) 15 (88.2 %)
 GBMO 2 (11.1 %) 1 (5.9 %)
 Gliosarcoma 2 (11.1 %) 1 (5.9 %)
Type >0.999
 Primary 16 (88.9 %) 15 (88.2 %)
 Recurrent 2 (11.1 %) 2 (11.8 %)
Molecular markers
 IDH1
  Wild type 18 (100 %) 17 (100 %)
  Mutation 0 0
1p19q >0.999
 No deletion 16 (88.9 %) 15 (88.2 %)
 Codeletion 2 (11.1 %) 2 (11.8 %)
MGMT promotor 0.358
 Unmethylated 10 (55.6 %) 12 (70.6 %)
 Methylated 8 (44.4 %) 5 (29.4 %)
P53 mutation 0.443
 Wild type 3 (16.7 %) 5 (29.4 %)
 Positive by IHC 15 (84.3 %) 12 (70.6 %)
EGFR mutation 0.193
 Wild type 8 (44.4 %) 4 (23.5 %)
 Positive by FISH 10 (55.6 %) 13 (76.5 %)
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independent two-sample t test for continuous variables 
and Chi square test (Fisher’s exact test) for categorical vari-
ables. Youden’s method in conjunction with receiver-oper-
ating characteristic (ROC) analysis was used to determine 
the optimal cut-off weight of fresh specimens for isolation 
of TSs to maximize sensitivity and specificity. All statistical 
analysis were performed using SAS version 9.2 software 
(SAS Institute Inc. Cary, NS, USA), MedCalc version 15.0 
software (MedCalc Software, Ostend, Belgium) and SPSS 
version 18.0 KO software (SPSS Korea, Seoul, Korea), with 
P < 0.05 considered statistically significant.
Results
Patient population
A total of 35 fresh surgical specimens were collected 
from 20 males and 15 females, ranging in age from 33 to 
77  years, during the period of October 2014 to August 
2015. Pathological diagnoses included GBM (n  =  29), 
GBM with an oligodendroglial component (n  =  3), and 
gliosarcomas (n = 3). There were 31 primary and 4 recur-
rent types of WHO IV gliomas. Of these 35 specimens, 
18 were categorized as positive and 17 as negative for TS 
isolation (Table  1). Molecular factors, including IDH-1 
mutation, MGMT promotor methylation, EGFR, p53, 1p 
and 19q LOH were evaluated. There were no statistically 
significant differences in age (P = 0.088), sex (P = 0.845), 
pathological diagnosis (P > 0.999), type (P > 0.999), 1p 19q 
codeletion (P  >  0.999), MGMT promotor methylation 
(P  =  0.358), p53 (P  =  0.443), or EGFR mutation status 
(P = 0.193) between TS-positive and TS-negative groups.
Characterization of GBM TSs
Cells isolated from tumor specimens yielded spheroids 
when cultured in TS complete media (Fig. 1a). An immu-
nocytochemical analysis of a representative TS sample 
(TS15-88) identified cells expressing markers associated 
with stem cells and brain tumor stem cells, including 
CD133 and nestin (Fig. 1b). To assess the multilineage dif-
ferentiation capacity of TSs, we cultured them in neuro-
glial differentiation media, as described in “Methods” 
section, and analyzed them for the expression of the dif-
ferentiation markers TUBB3 (immature neurons), GFAP 
(astrocytes), MBP (oligodendrocytes), and NeuN (mature 
neurons) by immunocytochemical staining (Fig. 1c). The 
GBM specimen from which this TS sample was derived 
was evaluated by IHC staining for CD133, CD15 and nes-
tin (Fig. 1d), which showed that all of these markers were 
well expressed in this GBM specimen.
Weights of fresh specimens
The average weights of fresh specimens were 
327  ±  266.8  mg in the TS-positive group and 
578.2 ± 543.2 mg in the TS-negative group (Fig. 2). Our 
original expectation was that the greater the weight of 
the sample, the more likely the isolation of TSs. Con-
trary to our expectations, the mean weight for the 
TS-negative group trended larger than that for the TS-
positive group, although this difference did not reach 
statistical significance (P = 0.245). Thus, our data indi-
cate no association of the weight of specimens with the 
ability to isolate TSs.
The optimal weight of specimens for TS isolation
The optimal cut-off value for isolation of TSs was deter-
mined by measuring the area under the ROC curve of 
0.618 (Fig. 3). This translated to an optimal fresh speci-
men weight of 500  mg for isolation of TSs, with a sen-
sitivity of 88.9  % and specificity of 41.2  %. In contrast 
to our initial hypothesis that larger specimens would be 
associated with higher rates of TS isolation, we found 
that the sensitivity and specificity of TS isolation was 
actually higher in specimens weighing less than 500 mg 
than in those greater than 500 mg.
Discussion
It has been assumed that TSs arise from a subpopulation 
of cells responsible for the initiation, maintenance, and 
recurrence of tumors [2, 18]. It is also commonly thought 
that TS-generating cells comprise some proportion of the 
tumor, and that a higher proportion of these TS-gener-
ating cells would be associated with a more aggressive 
tumor [3, 15, 19]. A previous study reported a significant 
increase in TS isolation rate in gliomas with increased 
WHO grades [3]. This suggested the related hypoth-
esis that a larger specimen mass would tend to favor an 
increased TS isolation rate. Our test of this hypothesis, 
however, revealed no significant difference in specimen 
weights between TS-positive and -negative groups. We 
also found that the two groups were not different with 
respect to clinical characteristics, molecular factors, or 
pathological features that might influence TS isolation.
Siedel et  al. [12] reported that most tumor samples 
with a size up to 0.5 cm3 are suitable for GBM TSs iso-
lation. Some authors recommend 200- to 500-mg speci-
mens for isolation of GBM TSs [11], and there have been 
some suggestions about the weight or volume of speci-
mens for isolation of TSs from other kinds of cancers [5, 
9, 20]. Most other TS-related studies have provided no 
description of the weight or volume of fresh specimens 
for TS isolation [19, 21–24]. Generally speaking, reports 
such as those referred to above have assumed that, all 
other things being equal, larger specimens are better than 
smaller specimens for TS isolation [5, 7, 9, 11, 12]. How-
ever, no studies have compared TS-negative and -positive 
groups to establish optimal weights or volumes for TS 
isolation.
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It is difficult to isolate TSs, and the efficacy of the pro-
cedure is low (from 1 to 30 %) [23, 25, 26]. Most studies 
on malignant tumors of the brain and other organs have 
reported TS isolation efficiencies up to 40–60  % [2, 3, 
9, 15, 27, 28], similar to the results of the results of our 
current study. However, some authors have described 
sequential modifications of isolation techniques that 
improved efficiency from 40 to 90  % in GBM patients 
[18]. In this latter case, improvements in TS isolation 
involved fixes to technical problems associated with each 
stage, such as early vulnerability of surgical specimens, 
mechanical disruption, and removal of red blood cells 
Fig. 1 Characterization of a representative GBM TS (TS15‑88). a Morphology of TSs shown by phase‑contrast microscopy (×100 original magni‑
fication). b Immunocytochemical staining of TSs for CD133 and nestin; nuclei were counterstained with DAPI (×100 original magnification). c TSs 
grown in neural differential media were immunostained for GFAP, MBP, NeuN, and TUBB3 (×200 original magnification). d IHC staining for CD133, 
CD15 and nestin in the GBM specimen from which this TS sample (TS15‑88) was isolated, showing that these markers were well expressed (×200, 
×400 original magnification) in this GBM specimen
Fig. 2 Weight distributions of fresh specimens in the two groups. 
There was no significant difference in the weight of surgical samples 
in the two groups (P = 0.245, Mann–Whitney test)
Fig. 3 Receiver‑operating characteristic curve for isolation of TSs. The 
optimal cut‑off value to maximize the sensitivity and specificity of TS 
isolation from WHO IV gliomas was 500 mg
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and necrotic material from fresh specimens. Although 
studies such as this highlight the contribution of tech-
nical problems to the isolation of TSs, the fact that the 
ability to isolate TSs is correlated with poorer clinical 
outcome in various types of cancers [3, 15, 29–33] indi-
cates that success of TS isolation is not solely determined 
by technical issues.
Previous report proposed that primary GBM TSs iso-
lation is a prognostic indicator of clinical outcome [15]. 
In addition, some authors described that TSs isolation is 
supposed to be a poor prognostic factor in other malig-
nant gliomas [34]. In the current study, we evaluated the 
prognostic role of TSs in WHO grade IV gliomas. TS 
isolation from WHO grade IV gliomas were not signifi-
cantly related to overall survival (data not shown), and 
there were no significant differences in clinical character-
istics, molecular factors, or pathological features between 
TS-positive and TS-negative groups (Table 1). However, 
these results could be related to the short follow-up 
period (10  month), suggesting that long-term follow-up 
of this cohort is needed to assess the prognostic role of 
TS isolation in patients with WHO grade IV gliomas.
There are some concerns that surgical procedures used 
to collect fresh specimens can affect TS isolation. Some 
authors have reported that surgical procedures can help 
TSs exit from quiescence, inducing the formation of 
more TSs for analysis consequently [19]. On the other 
hand, surgically resected tissue is vulnerable to rapid 
ischemic and degenerative alterations [7, 19]. Thus, opti-
mal conditions, including rapid transfer of specimens fol-
lowing surgical resection, removal of red blood cells and 
necrotic material and an appropriate environment for 
growth are required for the isolation of TSs from fresh 
surgical specimens [5, 7, 9, 11, 12, 18, 19, 23, 35]. Our 
laboratory has an ongoing effort to develop optimal con-
ditions for the isolation of TS [2, 3, 10, 17].
RNA sequencing or gene expression arrays could be 
helpful in validating new TS markers and targets. How-
ever, the genome analyses necessary to establish tran-
scription factors that might influence to TS isolation have 
not been performed. In this context, it has been shown 
that functional inhibition of microRNA-138 (miR-138) 
in malignant glioma prevents TS formation in vitro and 
impedes tumorigenesis in  vivo [36]. In our study, we 
sought to determine whether the ability to isolate TSs dif-
fered depending on the weight of the specimen. However, 
further studies regarding transcription factors necessary 
for TS isolation are needed.
In our study, the specimen weight was 500 mg for the 
isolation of TSs to maximize sensitivity and specificity. 
This result was a little similar to the value reported by 
other authors [11]. Ideally, specimens would be subdi-
vided into various sizes and then cultured, or more than 
one specimen would be procured from a single patient. 
However, in actual practice, the operating room setting 
imposes limitations on specimen collection. We tried 
to collect specimens with a minimum of red blood cells 
and necrotic material, but this made it difficult to gather 
specimens of different sizes from each patient. There-
fore, we emphasized the absence of significant differences 
between demographic and clinical characteristics of two 
groups, and used the ROC curve for statistical process-
ing. An analysis of our data yielded an area under the 
ROC curve of 0.618, which demonstrated poor discrimi-
natory ability for the isolation of TSs [37, 38]. However, 
500  mg of fresh specimen proved to be optimal in our 
study, and our summary data showed no significant dif-
ference in weight between the TS-positive and TS-neg-
ative groups, clearly ruling out size/weight of sample as a 
determining factor in successful TS isolation. Our study 
suggests some methods for improving the efficiency of 
TS isolation in addition to stage-specific technical modi-
fications. Future studies using a larger numbers of cases 
are warranted to further address the relationship between 
the amount of fresh specimen and TS isolation rate.
Conclusion
Our initial hypothesis that a larger amount of specimen 
would translate to a higher rate of TS isolation proved to 
be incorrect. Instead, we found no relationship between 
the weight of specimen and TS isolation rate. Moreover, 
our data suggested that 500  mg of fresh specimen was 
optimal for isolation of TS with maximal sensitivity and 
specificity. The results of this study could provide use-
ful technical information for cellular immortalization of 
patients with WHO grade IV gliomas.
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